US academic health centres face challenges that may threaten the future vitality of the clinical research enterprise, but they are fighting back, says Diane Gershon.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013
Trials Open Access 21 June 2017
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
Diane Gershon is Assistant Editor, New Technology at Nature Medicine
- Diane Gershon
Rights and permissions
About this article
Cite this article
Gershon, D. From bench to bedside and back?. Nature 411, 4–5 (2001). https://doi.org/10.1038/35108132
Issue Date:
DOI: https://doi.org/10.1038/35108132
This article is cited by
-
Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013
Trials (2017)
-
Finance offers intellectual challenges and economic rewards
Nature Biotechnology (2001)